ALTHOUGH the prognosis in herpes simplex encephalitis remains unclear in view of problems inherent in providing laboratory confirmation of diagnoses,1 reports in current literature2-8 indicate the disease is severe, often fatal, frequently leaving survivors with neurological sequelae.
Until recently, treatment consisted largely of supportive care, with occasional administration of γ-globulin or hyperimmune plasma. During the past three years, several authors described beneficial results in herpes simplex encephalitis with systemic use of idoxuridine (5-iodo-2′-deoxyuridine).8-13 However, no one has reported experience with systemic use of idoxuridine in the premature infant. Partridge and Millis14 used intravenously administered idoxuridine in a combined, five-day course of intermittent and continuous infusion in a newborn term infant with systemic herpes simplex. The infant received a total dose of 580 mg/kg and showed clinical improvement, with no toxicity noted. The infant died later, probably from the effect of secondary bacterial infection.
This report presents
Tuffli GA, Nahmias AJ. Neonatal Herpetic Infection: Report of Two Premature Infants Treated With Systemic Use of Idoxuridine. Am J Dis Child. 1969;118(6):909–914. doi:10.1001/archpedi.1969.02100040911018
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: